Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 1
1(33.3%)
3Total
N/A(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT01312831Not ApplicableCompleted

Efficacy and Safety Study of Oral Eligen® B12 in Subjects With Low Serum Cobalamin

Role: lead

NCT01311739Not ApplicableCompleted

Oral Cyanocobalamin (Eligen B12) Bioavailability Study

Role: lead

NCT00982254Phase 1Completed

Oral Insulin: A Comparison With Subcutaneous Regular Human Insulin in Patients With Type 2 Diabetes

Role: collaborator

All 3 trials loaded